Researchers Find Second U.S. Patient Infected With 'Superbug' Gene
The mcr-1 gene makes bacteria highly resistant to the last-resort antibiotic called colistin, which is used to treat multi-drug-resistant infections.
Reuters
Scientists have identified a second patient in the United States infected with bacteria carrying the mcr-1 "superbug" gene, which makes bacteria highly resistant to a last-resort class of antibiotics.
The gene, found in a sample of E. coli bacteria from a patient in New York, follows the discovery late last month of a patient in Pennsylvania who had a urinary tract infection caused by E. coli that carried the gene.
Advertisement
The finding was published on Monday in Antimicrobial Agents and Chemotherapy, a journal of the American Society for Microbiology.
The mcr-1 gene makes bacteria resistant to colistin, an antibiotic used to treat multi-drug-resistant infections, including carbapenem-resistant Enterobacteriaceae or CRE, which U.S. health officials have dubbed a "nightmare" bacteria.
What is concerning about the mcr-1 gene discoveries in the United States is that bacteria have the capability to share resistance genes. U.S. officials are worried that the mcr-1 gene may find its way into CRE bacteria, potentially creating bacteria resistant to virtually all types of antibiotics.
Advertisement
Scientists have been tracking the mcr-1 gene's movement around the globe since it was discovered last year in people and pigs in China.
The latest U.S. finding of mcr-1 came as part of a global effort called the SENTRY Antimicrobial Surveillance Program, led by Mariana Castanheira of JMI Laboratories based in North Liberty, Iowa.
Researchers tested 13,525 Escherichia coli and 7,481 Klebsiella pneumoniae strains from patients collected last year from hospitals in the Asia-Pacific region, Latin America, Europe and North America.
Of these, 390, or 1.9 percent, were resistant to colistin, and 19 of these isolates tested positive for the mcr-1 gene.
Advertisement
Samples carrying the gene came from 10 countries and included some from each region. Only one came from the United States. It involved a New York patient infected with E. coli whose name and condition were not disclosed.
In both U.S. cases, bacteria that carried the "superbug" gene were resistant to colistin but susceptible to a number of other antibiotics, making the infections treatable.
To keep track of the spread of this resistance gene in the United States, the Centers for Disease Control and Prevention has disclosed plans to expand laboratory capacity to seven or eight regional laboratories, plus add capacity to laboratories in each U.S. state as well as seven cities or territories.
In the United States, antibiotic resistance causes at least 2 million illnesses and 23,000 deaths annually.
Support HuffPost
Our 2024 Coverage Needs You
Your Loyalty Means The World To Us
At HuffPost, we believe that everyone needs high-quality journalism, but we understand that not everyone can afford to pay for expensive news subscriptions. That is why we are committed to providing deeply reported, carefully fact-checked news that is freely accessible to everyone.
Whether you come to HuffPost for updates on the 2024 presidential race, hard-hitting investigations into critical issues facing our country today, or trending stories that make you laugh, we appreciate you. The truth is, news costs money to produce, and we are proud that we have never put our stories behind an expensive paywall.
As Americans head to the polls in 2024, the very future of our country is at stake. At HuffPost, we believe that a free press is critical to creating well-informed voters. That's why our journalism is free for everyone, even though other newsrooms retreat behind expensive paywalls.
Our journalists will continue to cover the twists and turns during this historic presidential election. With your help, we'll bring you hard-hitting investigations, well-researched analysis and timely takes you can't find elsewhere. Reporting in this current political climate is a responsibility we do not take lightly, and we thank you for your support.
Thank you for your past contribution to HuffPost. We are sincerely grateful for readers like you who help us ensure that we can keep our journalism free for everyone.
The stakes are high this year, and our 2024 coverage could use continued support. Would you consider becoming a regular HuffPost contributor?
Dear HuffPost Reader
Thank you for your past contribution to HuffPost. We are sincerely grateful for readers like you who help us ensure that we can keep our journalism free for everyone.
The stakes are high this year, and our 2024 coverage could use continued support. If circumstances have changed since you last contributed, we hope you’ll consider contributing to HuffPost once more.